
|Videos|December 16, 2022
Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial
Author(s)Neal Shore, MD, FACS
Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
5












